While some orthopedic and spine surgeons are divided on how medications used for weight loss, including Ozempic and Wegovy, will shape the field, it is undeniable that the drugs are playing an ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

When I tell people I direct clinical research studies, I often encounter surprise. “Aren’t you a physician?” they ask. It ...

Trulicity (dulaglutide) is a prescription drug that can cause weight loss in some people but is not approved for this use.

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

Glucagon-like peptide-1 receptor agonists, also known as GLP-1 drugs, are a class of drugs initially developed for treating type 2 diabetes and have since gained recognition for achieving excellent ...

Currently, there are two approved GLP-1 and one combined GIP/ GLP-1 receptor agonists indicated for ... monitored and the potential for weight rebound and loss of beneficial cardiovascular effects ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...

Weight loss due to exenatide was less prominent in phase 3 ... whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 receptor agonists. This possibility is ...